Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Feb 10;5(3):346-350.
doi: 10.1002/ccr3.839. eCollection 2017 Mar.

Real-world use of idarucizumab for dabigatran reversal in three cases of serious bleeding

Nicolas Gendron  1 , Anne Laure Feral-Pierssens  2 , Igor Jurcisin  3 , Emmanuelle de Raucourt  4 , Valerie Bouton  5 , Anne Marie Fischer  6 , Camille Lorenceau-Savale  7 , Agnès Lillo-Le Louët  8 , David M Smadja  1
Affiliations
Case Reports

Real-world use of idarucizumab for dabigatran reversal in three cases of serious bleeding

Nicolas Gendron et al. Clin Case Rep. .

Abstract

Bleeding is a rare complication of direct oral anticoagulant potentially associated with high mortality rates. Biological monitoring is necessary for more than 24 h after idarucizumab antidote therapy in case of bleeding with dabigatran therapy.

Keywords: Anticoagulant; antidote; bleeding; dabigatran; idarucizumab; non‐VKA oral anticoagulants.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Plasma dabigatran concentration and thrombin time in patients treated with idarucizumab. The Hemoclot® Thrombin Inhibitor assay limit of quantification was defined as 30 ng/mL (red dotted line). (A) Plasma dabigatran concentration and thrombin time in patient 1 (gastrointestinal bleeding). (B) Plasma dabigatran concentration and thrombin time in patient 2 (gastrointestinal bleeding). (C) Plasma dabigatran concentration and thrombin time in patient 3 (intracerebral bleeding).
See this image and copyright information in PMC

References

    1. Schiele, F. , van Ryn J., Canada K., Newsome C., Sepulveda E., Park J., et al. 2013. A specific antidote for dabigatran: functional and structural characterization. Blood 121:3554–3562. - PubMed
    1. Pollack, C. V. Jr , Reilly P. A., Eikelboom J., Glund S., Verhamme P., Bernstein R. A., et al. 2015. Idarucizumab for dabigatran reversal. N. Engl. J. Med. 373:511–520. - PubMed
    1. Levy, J. H. , Ageno W., Chan N. C., Crowther M., Verhamme P., and Weitz J. I.. 2016. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J. Thromb. Haemost. 14:623–627. - PubMed
    1. Glund, S. , Moschetti V., Norris S., Stangier J., Schmohl M., van Ryn J., et al. 2015. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb. Haemost. 113:943–951. - PubMed
    1. Granger, C. B. , Alexander J. H., McMurray J. J., Lopes R. D., Hylek E. M., Hanna M., et al. 2011. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365:981–992. - PubMed

Publication types

LinkOut - more resources